Trial Profile
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2022
Price :
$35
*
At a glance
- Drugs Spartalizumab (Primary)
- Indications Gastrointestinal cancer; Lung cancer; Malignant thymoma; Neuroendocrine carcinoma; Neuroendocrine tumours; Pancreatic cancer; Thoracic neoplasms
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Nov 2020 This trial has been Discontinued in Netherlands, according to European Clinical Trials Database record.
- 28 Jun 2020 This trial has been discontinued in Sweden.
- 23 Jun 2020 Status changed from active, no longer recruiting to completed.